JP2013510856A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510856A5
JP2013510856A5 JP2012538889A JP2012538889A JP2013510856A5 JP 2013510856 A5 JP2013510856 A5 JP 2013510856A5 JP 2012538889 A JP2012538889 A JP 2012538889A JP 2012538889 A JP2012538889 A JP 2012538889A JP 2013510856 A5 JP2013510856 A5 JP 2013510856A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
composition according
condition
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012538889A
Other languages
English (en)
Japanese (ja)
Other versions
JP5956928B2 (ja
JP2013510856A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/055996 external-priority patent/WO2011059969A2/en
Publication of JP2013510856A publication Critical patent/JP2013510856A/ja
Publication of JP2013510856A5 publication Critical patent/JP2013510856A5/ja
Application granted granted Critical
Publication of JP5956928B2 publication Critical patent/JP5956928B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012538889A 2009-11-13 2010-11-09 哺乳類のステロイドの代謝物質 Expired - Fee Related JP5956928B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26126209P 2009-11-13 2009-11-13
US61/261,262 2009-11-13
PCT/US2010/055996 WO2011059969A2 (en) 2009-11-13 2010-11-09 Mammalian metabolites of steroids

Publications (3)

Publication Number Publication Date
JP2013510856A JP2013510856A (ja) 2013-03-28
JP2013510856A5 true JP2013510856A5 (enExample) 2013-12-26
JP5956928B2 JP5956928B2 (ja) 2016-07-27

Family

ID=43992357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012538889A Expired - Fee Related JP5956928B2 (ja) 2009-11-13 2010-11-09 哺乳類のステロイドの代謝物質

Country Status (8)

Country Link
US (2) US20120282331A1 (enExample)
EP (1) EP2499151A4 (enExample)
JP (1) JP5956928B2 (enExample)
CN (1) CN102822190B (enExample)
AU (1) AU2010319697B2 (enExample)
BR (1) BR112012012167A2 (enExample)
CA (1) CA2780365A1 (enExample)
WO (1) WO2011059969A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
SG11201507093WA (en) * 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3200801B1 (en) * 2014-10-02 2024-04-24 University of Maryland, Baltimore Methods of treating pancreatic cancer
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯-3-醇的盐及其制备方法
CN112851741B (zh) * 2016-02-19 2022-10-25 深圳市塔吉瑞生物医药有限公司 一种取代的甾体类化合物及其应用
CN111454315B (zh) * 2020-04-15 2022-12-09 宁波第二激素厂 一种雄甾-16-烯-3β-醇的合成方法
CN116621902A (zh) * 2022-05-18 2023-08-22 上海醇健实业发展有限公司 17-苯并咪唑基-10α-甲基-甾体衍生物及其制备方法、用途和药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3480621A (en) * 1967-01-17 1969-11-25 Phytogen Prod Inc Steroid ketal
GB2265624B (en) * 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
DE4232681C2 (de) * 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DK2206719T3 (en) * 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
WO2009114658A2 (en) * 2008-03-12 2009-09-17 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20110118219A1 (en) * 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
GB201114153D0 (en) * 2009-02-05 2011-10-05 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent

Similar Documents

Publication Publication Date Title
JP2013510856A5 (enExample)
JP2013501722A5 (enExample)
JP2011528658A5 (enExample)
JP2013518832A5 (enExample)
JP2012516900A5 (enExample)
JP2016535031A5 (enExample)
JP2015500843A5 (enExample)
JP2010536766A5 (enExample)
JP2009530345A5 (enExample)
JP2010077141A5 (enExample)
JP2014508752A5 (enExample)
JP2013542261A5 (enExample)
RU2015151502A (ru) Химические соединения
JP2014532638A5 (enExample)
JP2019516735A5 (enExample)
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
JP2017517565A5 (enExample)
JP2019535723A5 (enExample)
JP2017513824A5 (enExample)
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
JP2010521516A5 (enExample)
RU2012128887A (ru) Способ получения гидрохлорида моксифлоксацина и его промежуточных продуктов
NZ603261A (en) Anticancer steroidal lactones unsaturated in position 7 (8)
WO2018071315A3 (en) Piperidine derivatives as liver x receptor beta agonists, compositions, and their use
WO2014001215A3 (en) 3-o-heteroaryl-ingenol